• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

被浪费的钱:加拿大的仿制药价格

Money left on the table: generic drug prices in Canada.

作者信息

Law Michael R

机构信息

Centre for Health Services and Policy Research, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.

出版信息

Healthc Policy. 2013 Feb;8(3):17-25.

PMID:23968624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3999558/
Abstract

BACKGROUND

Generic drugs are a major cost-saving opportunity for patients and drug plans. While almost every province has reduced generic drug prices, we have no information on whether these new prices are internationally competitive. Therefore, I compared Canadian prices to those in two other countries.

METHODS

I used 2009 data from the IMS Brogan Canadian CompuScript and PharmaStat databases and studied the 100 most frequently dispensed generic products in Ontario, which has Canada's lowest generic prices. I compared these prices to those in public drug programs in the United States and New Zealand that use tendering. Using these alternative prices, I calculated the potential savings in Ontario.

RESULTS

Of the top 100 generic products, 82 were listed on an international formulary. In 90% of cases, generic products were less expensive in other countries. If Ontario had obtained the lowest comparator price for these products, the annual public sector and overall drug expenditure savings would have been $129 million and $245 million, respectively. Further, the province could have publicly paid for all these generic drugs - both public and private - and saved $87 million compared to current public sector expenditures.

DISCUSSION

Even after recent reforms, generic drug prices in Canada remain high by international standards. I found that if Ontario had obtained commonly used generic drugs at international best prices, the province could have publicly paid for all generic drugs and lowered annual expenditures by nearly a quarter-billion dollars.

摘要

背景

仿制药对于患者和药品计划而言是一个主要的成本节约机会。尽管几乎每个省份都降低了仿制药价格,但我们并不清楚这些新价格在国际上是否具有竞争力。因此,我将加拿大的价格与另外两个国家的价格进行了比较。

方法

我使用了来自IMS Brogan加拿大CompuScript和PharmaStat数据库的2009年数据,研究了安大略省(该省仿制药价格在加拿大最低)最常配发的100种仿制药产品。我将这些价格与美国和新西兰采用招标方式的公共药品计划中的价格进行了比较。利用这些替代价格,我计算了安大略省潜在节省的费用。

结果

在100种最畅销的仿制药产品中,有82种被列入国际药品目录。在90%的情况下,其他国家的仿制药价格更低。如果安大略省为这些产品获得了最低的比较价格,那么公共部门每年节省的支出和总体药品支出分别将达到1.29亿加元和2.45亿加元。此外,该省本可以为所有这些仿制药(包括公共和私人的)支付费用,与目前公共部门的支出相比可节省8700万加元。

讨论

即使经过最近的改革,按照国际标准,加拿大的仿制药价格仍然很高。我发现,如果安大略省以国际最优价格获得常用仿制药,该省本可以为所有仿制药支付费用,并将年度支出降低近2.5亿加元。

相似文献

1
Money left on the table: generic drug prices in Canada.被浪费的钱:加拿大的仿制药价格
Healthc Policy. 2013 Feb;8(3):17-25.
2
The short-term impact of Ontario's generic pricing reforms.安大略省药品通用定价改革的短期影响。
PLoS One. 2011;6(7):e23030. doi: 10.1371/journal.pone.0023030. Epub 2011 Jul 28.
3
The effect of generic competition on the price of brand-name drugs.仿制药竞争对品牌药价格的影响。
Health Policy. 2004 Apr;68(1):47-54. doi: 10.1016/j.healthpol.2003.07.007.
4
Private expenditures on brand name prescription drugs after generic entry.仿制药上市后品牌名处方药的私人支出。
Appl Health Econ Health Policy. 2013 Oct;11(5):523-9. doi: 10.1007/s40258-013-0052-y.
5
Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.在加拿大现有公共药品计划中增加基本药物清单的全民公共覆盖的估计效果。
CMAJ. 2017 Feb 27;189(8):E295-E302. doi: 10.1503/cmaj.161082.
6
Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.在巴西免费且普遍可获得艾滋病治疗的背景下抗逆转录病毒药物成本的演变
PLoS Med. 2007 Nov 13;4(11):e305. doi: 10.1371/journal.pmed.0040305.
7
Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.用通用名药物替代品牌名药物可能节省的费用:1997 - 2000年医疗支出小组调查
Ann Intern Med. 2005 Jun 7;142(11):891-7. doi: 10.7326/0003-4819-142-11-200506070-00006.
8
Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?在选定的发展中国家中,将品牌原研药转换为通用等效药物:可以节省多少费用?
Value Health. 2012 Jul-Aug;15(5):664-73. doi: 10.1016/j.jval.2012.04.004. Epub 2012 Jul 11.
9
Do generics offer significant savings to the UK National Health Service?仿制药能为英国国民医疗服务体系大幅节省开支吗?
Curr Med Res Opin. 2007 Jan;23(1):105-16. doi: 10.1185/030079907X159506.
10
Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.在药品福利计划中为同等效果支付更高价格的成本。
Aust Health Rev. 2017 Mar;41(1):1-6. doi: 10.1071/AH15122.

引用本文的文献

1
A comparison of generic drug prices in seven European countries: a methodological analysis.七个欧洲国家仿制药价格比较:方法学分析
BMC Health Serv Res. 2017 Mar 31;17(1):242. doi: 10.1186/s12913-017-2184-5.
2
The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000-2011.2000 - 2011年加拿大药物创新对癌症过早死亡率的影响
Int J Health Econ Manag. 2015 Sep;15(3):339-359. doi: 10.1007/s10754-015-9172-2. Epub 2015 Jun 26.
3
Universal prescription drug coverage in Canada: Long-promised yet undelivered.加拿大全民处方药保险:承诺已久却未实现。
Healthc Manage Forum. 2016 Nov;29(6):247-254. doi: 10.1177/0840470416658907. Epub 2016 Oct 15.
4
Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.六种治疗复发性艰难梭菌感染策略的成本效益分析
PLoS One. 2016 Feb 22;11(2):e0149521. doi: 10.1371/journal.pone.0149521. eCollection 2016.
5
Canada's New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem.加拿大新的仿制药定价政策:应对棘手问题的合理方法。
Healthc Policy. 2015 Aug;11(1):10-4.
6
Bias within economic evaluations - the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug.经济评估中的偏差——考虑低成本仿制药未来进入市场对新药当前估计的增量成本效益比的影响。
Clinicoecon Outcomes Res. 2015 Oct 6;7:497-503. doi: 10.2147/CEOR.S90386. eCollection 2015.
7
Generic drugs in Canada: an examination of tiered pricing.加拿大的仿制药:分层定价研究。
CMAJ. 2015 Oct 6;187(14):1033-1034. doi: 10.1503/cmaj.150395. Epub 2015 Jul 13.
8
Pan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicines.泛加拿大药品定价过高:一项关于仿制药成本控制的六国研究。
Open Med. 2014 Oct 14;8(4):e130-5. eCollection 2014.

本文引用的文献

1
The road to competitive generic drug prices in Canada.加拿大实现仿制药价格具有竞争力的道路。
CMAJ. 2013 Sep 17;185(13):1141-4. doi: 10.1503/cmaj.121367. Epub 2012 Nov 19.
2
Purchasing prescription drugs in Canada: hang together or hang separately.在加拿大购买处方药:团结还是分裂。
Healthc Policy. 2011 May;6(4):22-6.
3
The effect of cost on adherence to prescription medications in Canada.加拿大的药物依从性受成本因素的影响。
CMAJ. 2012 Feb 21;184(3):297-302. doi: 10.1503/cmaj.111270. Epub 2012 Jan 16.
4
Provincial squeeze on generic prices continues.省级层面针对仿制药价格的挤压仍在持续。
CMAJ. 2011 Oct 4;183(14):E1049-50. doi: 10.1503/cmaj.109-3966. Epub 2011 Sep 6.
5
The potential economic impact of restricted access to angiotensin-receptor blockers.血管紧张素受体阻滞剂获取受限的潜在经济影响。
CMAJ. 2011 Feb 22;183(3):E180-6. doi: 10.1503/cmaj.100787. Epub 2011 Jan 24.
6
Costs and benefits of free medications after myocardial infarction.心肌梗死后免费药物的成本与效益
Healthc Policy. 2009 Nov;5(2):68-86.
7
Long-term trends in use of and expenditures for cardiovascular medications in Canada.加拿大心血管药物使用情况及支出的长期趋势。
CMAJ. 2009 Jul 7;181(1-2):E19-28. doi: 10.1503/cmaj.081913.
8
Influencing Drug Prices through Formulary-Based Policies: Lessons from New Zealand.通过基于处方集的政策影响药品价格:来自新西兰的经验教训。
Healthc Policy. 2007 Aug;3(1):e121-40.
9
Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.心血管疾病中使用的仿制药和品牌药的临床等效性:一项系统评价和荟萃分析。
JAMA. 2008 Dec 3;300(21):2514-26. doi: 10.1001/jama.2008.758.
10
Sources of variation in provincial drug spending.
CMAJ. 2004 Feb 3;170(3):329-30.